Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: JACC Heart Fail. 2014 Feb 1;2(1):49–61. doi: 10.1016/j.jchf.2013.08.008

Figure 3. Therapeutic Benefit of NF Donor, MI, and HF CDCs in Mice With MI.

Figure 3

(A) Representative Masson's trichrome–stained myocardial sections 3 weeks after treatment with Control (vehicle only), NF donor, MI, and HF CDCs. Scar tissue and viable myocardium are identified by the blue and red colors, respectively. Snapshots of the infarct border zone (black box area) are presented beneath each group. (B–E) Quantitative analysis of infarct thickness, scar mass, viable tissue mass, and scar size from the Masson's trichrome–stained images (n = 6 animals per group). Left ventricular ejection fraction (LVEF) was measured by echocardiography at baseline (4 h post-MI) (F) and 3 weeks afterwards (G) (Control: n = 11 animals; NF donor, MI, or HF CDC: n = 19 to 24 animals from n = 6 patient-derived CDC lines). Baseline LVEFs were indistinguishable in the 4 groups. (H) Representative echocardiography images. *p < 0.05 compared with Control; **p < 0.05 compared with all other groups. Data are presented as means ± SD. Abbreviations as in Figure 1.